iShares US Pharmaceuticals ETF
95 hedge funds and large institutions have $96.2M invested in iShares US Pharmaceuticals ETF in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 7 closing their positions.
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
16% more funds holding
Funds holding: 82 → 95 (+13)
0% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 24
35% less capital invested
Capital invested by funds: $147M → $96.2M (-$50.9M)
44% less call options, than puts
Call options by funds: $451K | Put options by funds: $800K
58.99% less ownership
Funds ownership: 140.12% → 81.14% (-59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$6.44M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.24M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$3.32M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.77M |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$741K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$66.5M |
| 2 |
RCYC
Richard C. Young & Co
Newport,
Rhode Island
|
-$3.82M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.89M |
| 4 |
SCP
Syntal Capital Partners
Midland,
Texas
|
-$2.48M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.38M |
IHE Hedge Fund Activity: Q4 2019 in Review
95 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2019, worth a combined $96.2M — down 35% from $147M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new IHE positions and 7 closed out — a net gain of 16 holders — while 24 added to existing stakes and 24 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $6.44M. The largest seller was Goldman Sachs, cutting an estimated $66.5M.
- 95 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2019, up from 82 in Q3 2019.
- Funds reported $96.2M of iShares US Pharmaceuticals ETF stock for Q4 2019, down 35% quarter-over-quarter.
- 23 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2019 and 7 closed out, a net change of +16 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2019 was Fisher Asset Management, an estimated $6.44M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2019 was Goldman Sachs, an estimated $66.5M sold.
Based on aggregated 13F filings for Q4 2019.